Håkan Mellstedt

Publications
CV
Public outreach and news

Articles

Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia.

Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Sallberg Chen M; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: PHARMACEUTICS. 2023;15(4):1148

A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.

Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Manouchehri Doulabi E; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Article: PHARMACEUTICS. 2022;14(10):2238

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.

Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Österborg A; Hojjat-Farsangi M; Mellstedt H
Article: EJHAEM. 2021;2(3):525-529

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Lundin J; Mulder TA; Kättström M; Wästerlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Österborg A
Article: EJHAEM. 2021;2(3):498-502

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1+ CLL cells.

Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
Article: CELL DEATH & DISEASE. 2021;12(6):577

Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.

Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99

Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.

Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: BIOMEDICINES. 2020;8(6):E170-170

ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.

Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vågberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Österborg A; Hojjat-Farsangi M; Mellstedt H
Article: IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES. 2020;23(6):800-809

Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.

Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
Article: LEUKEMIA. 2018;32(10):2291-2295

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.

Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vågberg J; Byström S; Olsson E; Löfberg C; Norström C; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
Article: PLOS ONE. 2018;13(6):e0198038

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.

Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Österborg A; Mellstedt H
Article: HAEMATOLOGICA. 2017;102(3):562-572

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
Article: PLOS ONE. 2017;12(1):e0169736

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.

Ullenhag GJ; Mozaffari F; Broberg M; Mellstedt H; Liljefors M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(1):91-102

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788

Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Högfeldt T; Jaing C; Loughlin KM; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Österborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957

Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.

Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Österborg A; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Article: PLOS ONE. 2015;10(11):e0142310

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.

Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(11):3394-3408

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2014;45(3):1293-1303

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

Staff C; Mozaffari F; Frödin J-E; Mellstedt H; Liljefors M
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(7):1828-1835

Awareness and understanding of cancer immunotherapy in Europe.

Mellstedt H; Gaudernack G; Gerritsen WR; Huber C; Melero I; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C
Article: JOURNAL OF GYNECOLOGIC ONCOLOGY. 2014;25(3):221-228

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
Article: LEUKEMIA & LYMPHOMA. 2014;55(5):1158-1165

Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.

Högfeldt T; Johnsson P; Grandér D; Bahnassy AA; Porwit A; Eid S; Österborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2013;11(3):1-11

Clinical considerations for biosimilar antibodies.

Mellstedt H
Article: ANNALS OF ONCOLOGY. 2013;24 Suppl 5:v23-v28

Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.

Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2013;2(1):23

Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.

Mikaelsson E; Osterborg A; Tahmasebi Fard Z; Mahmoudi A; Mahmoudian J; Jeddi-Tehrani M; Akhondi M; Shokri F; Bishop PN; Rabbani H; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626

Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.

Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(5):797-802

Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.

Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J
Article: LEUKEMIA & LYMPHOMA. 2013;54(5):996-1003

Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

Högfeldt T; Bahnassy AA; Kwiecinska A; Osterborg A; Tamm KP; Porwit A; Zekri A-RN; Lundahl J; Khaled HM; Mellstedt H; Moshfegh A
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(1):51-63

T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile.

Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Österborg A; Choudhury A; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339

The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: PLOS ONE. 2013;8(6):e67601

A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.

Mikaelsson E; Österborg A; Jeddi-Tehrani M; Kokhaei P; Ostadkarampour M; Hadavi R; Gholamin M; Akhondi M; Shokri F; Rabbani H; Mellstedt H
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2012;32(4):855-865

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.

Staff C; Magnusson CGM; Hojjat-Farsangi M; Mosolits S; Liljefors M; Frödin J-E; Wahrén B; Mellstedt H; Ullenhag GJ
Article: LEUKEMIA. 2012;26(6):1348-1355

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.

Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi A-R; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):865-879

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria.

Palma M; Hansson L; Choudhury A; Näsman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widén K; Horváth R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Article: BLOOD. 2011;117(20):5463-5472

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Bagnara D; Kaufman MS; Calissano C; Marsilio S; Patten PEM; Simone R; Chum P; Yan X-J; Allen SL; Kolitz JE; Baskar S; Rader C; Mellstedt H; Rabbani H; Lee A; Gregersen PK; Rai KR; Chiorazzi N
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2011;38(4):1075-1081

Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer.

Jacobson TAS; Lundahl J; Mellstedt H; Moshfegh A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;151(4):327-335

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells.

Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(6):1599-1606

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

Wang B; Kokhaei P; Mellstedt H; Liljefors M
Article: MINERVA CHIRURGICA. 2009;64(6):643-653

Cancer vaccines for non-small-cell lung cancer.

Palma M; Choudhury A; Mellstedt H
Article: CANCER SCIENCE. 2009;100(12):2346-2353

Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.

Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536

Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.

Adamson L; Palma M; Choudhury A; Eriksson I; Näsman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(1):111-120

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.

Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(5):1190-1195

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

Daneshmanesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Article: AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY. 2008;60(2):160-171

Repertoire and clonality of T-cell receptor beta variable genes expressed in endometrium and blood T cells of patients with recurrent spontaneous abortion.

Dokouhaki P; Moghaddam R; Rezvany M; Ghassemi J; Novin MG; Zarnani A; Akhondi M-M; Ostadkarampour M; Mellstedt H; Razavi A; Jeddi-Tehrani M
Article: LEUKEMIA & LYMPHOMA. 2008;49(7):1360-1367

Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.

Shabani M; Asgarian-Omran H; Vossough P; Sharifian RA; Faranoush M; Ghragozlou S; Khoshnoodi J; Roohi A; Jeddi-Tehrani M; Mellstedt H; Rabbani H; Shokri F
Article: ANNALS OF ONCOLOGY. 2008;19(6):1172-1179

Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).

Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(3):379-388

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.

Liljefors M; Nilsson B; Mellstedt H; Frödin J-E
Article: CLINICAL LUNG CANCER. 2008;9 Suppl 1:S37-S44

The future of cancer vaccines for non-small-cell lung cancer: ongoing trials.

Choudhury A; Palma M; Mellstedt H
Article: SUPPORTIVE CARE IN CANCER. 2008;16(1):57-65

Immune response, depression and fatigue in relation to support intervention in mammary cancer patients.

Lindemalm C; Mozaffari F; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CYTOMETRY PART B-CLINICAL CYTOMETRY. 2007;72(6):450-457

Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia.

Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Osterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2007;79(5):371-381

Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.

Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(1):105-111

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy.

Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Helander I; Lekander M; Mikaelsson E; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2007;66(1):43-51

Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.

Hallermalm K; Johansson S; Bråve A; Ek M; Engström G; Boberg A; Gudmundsdotter L; Blomberg P; Mellstedt H; Stout R; Liu MA; Wahren B
Article: CLINICAL CANCER RESEARCH. 2007;13(12):3536-3544

Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies.

Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Article: IRANIAN BIOMEDICAL JOURNAL. 2007;11(2):125-129

Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients.

Rezvany MR; Kazemi A; Hajifathali A; Kaviani S; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510

Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.

Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.

Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: TUMOR BIOLOGY. 2007;28(6):318-326

Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia.

Shabani M; Asgarian-Omran H; Jeddi-Tehrani M; Vossough P; Faranoush M; Sharifian RA; Toughe GR; Kordmahin M; Khoshnoodi J; Roohi A; Tavoosi N; Mellstedt H; Rabbani H; Shokri F
Article: ANNALS OF ONCOLOGY. 2007;18 Suppl 1:i14-i21

Clinical signs and symptoms at diagnosis and its differential diagnosis.

Mellstedt H
Article: HAEMATOLOGICA. 2007;92(1):110-114

Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems.

Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485

Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.

Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2006;47(7):1229-1238

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.

Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Article: EUROPEAN RESPIRATORY JOURNAL. 2006;27(3):451-459

Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis.

Idali F; Wikén M; Wahlström J; Mellstedt H; Eklund A; Rabbani H; Grunewald J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2006;55(2):210-220

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil.

Mellstedt H; Choudhury A
Article: MEDICAL ONCOLOGY. 2006;23(2):273-282

Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.

Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
Article: CYTOTHERAPY. 2006;8(4):318-326

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.

Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Article: ONKOLOGIE. 2005;28 Suppl 4:4-8

[Active immunotherapy in patients with hematologic and solid neoplasms].

Mellstedt H; Veelken H
Article: BLOOD. 2005;105(12):4828-4835

Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.

Mikaelsson E; Danesh-Manesh AH; Lüppert A; Jeddi-Tehrani M; Rezvany M-R; Sharifian RA; Safaie R; Roohi A; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2005;54(6):557-570

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.

Mosolits S; Markovic K; Fagerberg J; Frödin J-E; Rezvany M-R; Kiaii S; Mellstedt H; Jeddi-Tehrani M
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(6):1581-1589

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin J-E
Article: IMMUNOLOGY. 2005;114(3):428-437

Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice.

Hansson M; Djerbi M; Rabbani H; Mellstedt H; Gharibdoost F; Hassan M; Depierre JW; Abedi-Valugerdi M
Article: MEDICAL ONCOLOGY. 2005;22(3):291-302

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Kiaii S; Choudhury A; Mozaffari F; Kimby E; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 2004;112(4):669-677

Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines.

Mosolits S; Campbell F; Litvinov SV; Fagerberg J; Crowe JS; Mellstedt H; Ellis JH
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2004;42(11):5394-5396

Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation.

Bogdanovic G; Priftakis P; Giraud G; Kuzniar M; Ferraldeschi R; Kokhaei P; Mellstedt H; Remberger M; Ljungman P; Winiarski J; Dalianis T
Article: LEUKEMIA. 2004;18(11):1810-1815

Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.

Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Osterborg A; Mellstedt H
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2004;25(3):703-711

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin J-E
Article: BLOOD. 2004;104(4):948-955

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: CLINICAL CANCER RESEARCH. 2004;10(16):5391-5402

Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.

Mosolits S; Markovic K; Frödin J-E; Virving L; Magnusson CGM; Steinitz M; Fagerberg J; Mellstedt H
Article: ANTICANCER RESEARCH. 2004;24(4):2375-2383

Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients.

Shetye JD; Liljefors ML; Emdin SO; Frödin J-E; Strigård K; Mellstedt HT; Porwit A
Article: CLINICAL CANCER RESEARCH. 2004;10(10):3273-3281

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

Ullenhag GJ; Frödin J-E; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2004;53(4):331-337

Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA.

Ullenhag GJ; Fagerberg J; Strigård K; Frödin J-E; Mellstedt H
Article: LEUKEMIA. 2004;18(3):484-490

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.

Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(3):315-324

Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage.

Mozaffari F; Hansson L; Kiaii S; Ju X; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: CYTOTHERAPY. 2004;6(4):363-371

Development of a technology platform for large-scale clinical grade production of DC.

Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;58(6):601-606

Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR.

Abdalla AO; Kiaii S; Hansson L; Rossmann ED; Jeddi-Tehrani M; Shokri F; Osterborg A; Mellstedt H; Rabbani H
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;104(2):351-358

Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.

Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
Article: INTERNATIONAL JOURNAL OF CANCER. 2003;105(5):717-723

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.

Liljefors M; Nilsson B; Hjelm Skog A-L; Ragnhammar P; Mellstedt H; Frödin J-E
Article: CLINICAL CANCER RESEARCH. 2003;9(7):2447-2456

Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.

Ullenhag GJ; Frödin J-E; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
Article: BLOOD. 2003;101(12):4930-4936

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma.

Hansson L; Rabbani H; Fagerberg J; Osterborg A; Mellstedt H
Article: BLOOD. 2003;101(11):4607-4610

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.

Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
Article: LEUKEMIA. 2003;17(5):894-899

Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.

Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
Article: BLOOD. 2003;101(3):1063-1070

Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia.

Rezvany M-R; Jeddi-Tehrani M; Wigzell H; Osterborg A; Mellstedt H
Article: DRUGS OF TODAY. 2003;39 Suppl C:1-16

Monoclonal antibodies in human cancer.

Mellstedt H
Article: JOURNAL OF CLINICAL VIROLOGY. 2003;26(1):71-77

BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist.

Priftakis P; Bogdanovic G; Kokhaei P; Mellstedt H; Dalianis T
Article: HEMATOLOGY JOURNAL. 2003;4(4):248-252

Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.

Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H; Myeloma Group of Central Sweden
Article: DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 2003;112:61-67

Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF.

Wadhwa M; Mellstedt H; Small E; Thorpe R
Article: BLOOD. 2002;100(3):768-773

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Lundin J; Kimby E; Björkholm M; Broliden P-A; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(5):255-262

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.

Skog A-LH; Wersäll P; Ragnhammar P; Frödin J-E; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(4):209-218

Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.

Mosolits S; Steinitz M; Harmenberg U; Ruden U; Eriksson E; Mellstedt H; Fagerberg J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(5):299-306

Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL).

Rossmann ED; Lewin N; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(5):493-502

Spontaneous downregulation of antibody/autoantibody synthesis in susceptible mice upon chronic exposure to mercuric chloride is not owing to a general immunosuppression.

Roether S; Rabbani H; Mellstedt H; Abedi-Valugerdi M
Article: HYBRIDOMA. 2002;21(2):99-101

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Frödin J-E; Fagerberg J; Hjelm Skog A-L; Liljefors M; Ragnhammar P; Mellstedt H
Article: CANCER RESEARCH. 2002;62(5):1364-1369

Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.

Ullenhag GJ; Frödin J-E; Strigård K; Mellstedt H; Magnusson CGM
Article: INTERNATIONAL JOURNAL OF CANCER. 2002;97(3):344-348

Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells.

Laytragoon-Lewin N; Rossmann ED; Castro J; Mellstedt H
Article: MEDICAL ONCOLOGY. 2002;19 Suppl:S21-S26

Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.

Osterborg A; Mellstedt H; Keating M
Article: DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 2002;109:79-86

Experience measuring antibodies to both drug and impurities and their clinical sequelae.

Wadhwa M; Ragnhammar P; Mellstedt H; Gallo P; Thorpe R
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(2):263-271

Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern.

Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Osterborg A; Rabbani H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;113(4):1020-1034

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.

Myeloma Trialists' Collaborative Group
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(5):342-346

Increased serum levels of soluble Fas in progressive B-CLL.

Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Article: CLINICAL CANCER RESEARCH. 2001;7(5):1163-1170

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.

Hjelm Skog AL; Wadhwa M; Hassan M; Gharizadeh B; Bird C; Ragnhammar P; Thorpe R; Mellstedt H
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74

Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.

Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; OIsterborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160

Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study.

Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Osterborg A
Article: HEMATOLOGY JOURNAL. 2001;2(5):300-306

Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.

Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(2):608-617

Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.

Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Osterborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(1):230-238

Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.

Rezvany MR; Jeddi-Tehrani M; Rabbani H; Rudén U; Hammarström L; Osterborg A; Wigzell H; Mellstedt H
Article: ANTICANCER RESEARCH. 2000;20(2B):1093-1100

Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.

Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
Article: ANNALS OF ONCOLOGY. 2000;11 Suppl 3:191-194

Monoclonal antibodies as enhancers of the host's immunoresponse against the tumour.

Mellstedt H
Article: MEDICAL ONCOLOGY. 1999;16(4):289-295

Cytokine expression in B-CLL in relation to disease progression and in vitro activation.

Aguilar-Santelises M; Gigliotti D; Osorio LM; Santiago AD; Mellstedt H; Jondal M
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;48(8):463-470

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.

Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Article: HUMAN GENE THERAPY. 1999;10(14):2325-2335

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.

Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
Article: CELLULAR IMMUNOLOGY. 1999;196(2):110-121

Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.

Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 1999;35 Suppl 3:S29-S32

Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man.

Mellstedt H; Fagerberg J; Osterborg A
Article: BLOOD. 1999;94(3):1063-1069

Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset.

Rezvany MR; Jeddi-Tehrani M; Osterborg A; Kimby E; Wigzell H; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1999;5(6):1353-1361

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.

Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(5):671-680

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.

Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;47(6):315-320

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma.

Mosolits S; Harmenberg U; Rudén U; Ohman L; Nilsson B; Wahren B; Fagerberg J; Mellstedt H
Article: PATHOLOGIE ET BIOLOGIE. 1999;47(2):211-215

Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.

Mellstedt H; Osterborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(12):3832-3842

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1998;47(3):131-142

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.

Samanci A; Yi Q; Fagerberg J; Strigård K; Smith G; Rudén U; Wahren B; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1998;61(4):266-271

Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.

Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(10):3257-3263

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 1998;4(8):1921-1929

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.

Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;76(6):909-912

bcl-2 rearrangement detected by pulsed-field gel electrophoresis (PFGF) in B-chronic lymphocytic leukemia (CLL) cells.

Laytragoon-Lewin N; Kashuba V; Mellstedt H; Klein G
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 1998;1(4):693-702

Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.

Zhao Q; Blomquist E; Bolander H; Gedda L; Hartvig P; Janson J; Lundqvist H; Mellstedt H; Nilsson S; Nistèr M; Sundin A; Tolmachev V; Westlin J; Carlsson J
Article: BLOOD. 1998;91(7):2459-2466

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.

Osterborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Article: IMMUNOLOGY LETTERS. 1998;60(2-3):73-79

Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes.

Tomita Y; Avila-Cariño J; Yamamoto K; Mellstedt H; Klein E
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;73(6):790-794

Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient.

Wersäll P; Fagerberg J; Ohlsson I; Rudén U; Boethius J; Mellstedt H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(9):2245-2252

T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.

Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;234(2):296-299

Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer.

Folkers K; Osterborg A; Nylander M; Morita M; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1997;44(3):157-164

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

Wersäll P; Ohlsson I; Biberfeld P; Collins VP; von Krusenstjerna S; Larsson S; Mellstedt H; Boethius J
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;71(3):345-349

Epstein-Barr virus (EBV) gene expression in lymphoid B cells during acute infectious mononucleosis (IM) and clonality of the directly growing cell lines.

Laytragoon-Lewin N; Chen F; Avila-Carino J; Klein G; Mellstedt H
Article: BLOOD. 1997;89(8):2833-2841

CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM.

Osorio LM; De Santiago A; Aguilar-Santelises M; Mellstedt H; Jondal M
Article: JOURNAL OF MOLECULAR MEDICINE-JMM. 1997;75(4):300-304

Gene therapy for glioblastoma [correction of gliobestome] multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir.

Stockhammer G; Brotchi J; Leblanc R; Bernstein M; Schackert G; Weber F; Ostertag C; Mulder NH; Mellstedt H; Seiler R; Yonekawa Y; Twerdy K; Kostron H; De Witte O; Lambermont M; Velu T; Laneuville P; Villemure JG; Rutka JT; Warnke P; Laseur M; Mooij JJ; Boëthius J; Mariani L; Gianella-Borradori A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1997;15(4):1567-1574

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;96(2):338-345

Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets.

Yi Q; Eriksson I; He W; Holm G; Mellstedt H; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1997;70(1):1-8

B-CLL cells with unusual properties.

Avila-Cariño J; Lewin N; Tomita Y; Szeles A; Sandlund A; Mosolits S; Mellstedt H; Klein G; Klein E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).

Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Article: IMMUNOLOGY LETTERS. 1996;54(1):45-52

B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes.

Avila-Cariño J; Andersson J; Mellstedt H; Klein E
Article: JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY. 1996;44(7):767-776

Retrieval of leukocyte antigens in paraffin-embedded rat tissues.

Shetye JD; Scheynius A; Mellstedt HT; Biberfeld P
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;69(2):114-119

Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression.

Aguilar-Santelises M; Rottenberg ME; Lewin N; Mellstedt H; Jondal M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(1):151-153

Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJ; Catovsky D; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1996;42(2):81-87

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.

Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(4):840-846

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.

Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(2):393-400

Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease.

Sjöberg J; Aguilar-Santelises M; Sjögren AM; Pisa EK; Ljungdahl A; Björkholm M; Jondal M; Mellstedt H; Pisa P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(1):71-76

Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation.

Isaksson E; Björkholm M; Holm G; Johansson B; Nilsson B; Mellstedt H; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(4):486-490

Epstein Barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPs but not EBNA2 in vivo.

Laytragoon-Lewin N; Chen F; Avila-Cariño J; Zou JZ; Mellstedt H; Ernberg I; Klein G
Article: ANNALS OF ONCOLOGY. 1995;6(9):895-899

Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.

Björkholm M; Axdorph U; Grimfors G; Merk K; Johansson B; Landgren O; Svedmyr E; Mellstedt H; Holm G
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1995;7(5):1049-1056

Different dose regimens of the mouse monoclonal-antibody 17-1a for therapy of patients with metastatic colorectal-carcinoma.

Ragnhammar P; Frodin J; Hjelm A; Fagerberg J; Wersall P; Lindemalm C; Nilsson B; Fox K; Magnusson I; Ewerth S; Thor K; Secher E; Mellstedt H
Article: BLOOD. 1995;86(8):3043-3049

Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.

Yi Q; Osterborg A; Bergenbrant S; Mellstedt H; Holm G; Lefvert AK
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.

Sangfelt O; Osterborg A; Grandér D; Anderbring E; Ost A; Mellstedt H; Einhorn S
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(6):765-772

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease.

Matsuda M; Petersson M; Lenkei R; Taupin JL; Magnusson I; Mellstedt H; Anderson P; Kiessling R
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1995;40(6):367-375

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Article: MEDICAL ONCOLOGY. 1995;12(2):69-77

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.

Wersäll P; Mellstedt H
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1995;92(11):4773-4777

Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.

Fagerberg J; Steinitz M; Wigzell H; Askelöf P; Mellstedt H
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;61(2):159-164

Detection of two Epstein-Barr-virus (EBV)-carrying leukemic cell clones in a patient with chronic lymphocytic leukemia (CLL).

Lewin N; Avila-Cariño J; Minarovits J; Lennette E; Brautbar C; Mellstedt H; Klein G; Klein E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1995;89(1):110-116

Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests.

Osterborg A; Yi Q; Bergenbrant S; Holm G; Lefvert AK; Mellstedt H
Article: CANCER BIOTHERAPY. 1995;10(1):5-12

Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.

Hjelm AL; Ragnhammar P; Fagerberg J; Magnusson I; Frodin JE; Svanstrom R; Shetye J; Mellstedt H; Wersall JP
Show more

All other publications

Corrigendum: CLINICAL CANCER RESEARCH. 2019;25(9):2939

Correction: Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor.

Ullenhag GJ; Frödin J-E; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H
Meeting abstract: BLOOD. 2018;132:4421

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients

Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M; Palma M; Heimersson K; Mellstedt H; Österborg A; Lundin J
Editorial comment: JOURNAL OF ONCOLOGY PRACTICE. 2017;13(9_suppl):15s-16s

European Perspective on Biosimilars.

Mellstedt H
Corrigendum: LEUKEMIA RESEARCH. 2017;57:127

Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].

Garcia C; Rosén A; Kimby E; Aguilar-Santelises M; Jondal M; Björkholm M; Holm G; Mellstedt H
Review: TUMOR BIOLOGY. 2017;39(5):1010428317699797-101042831769979

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE; Hill QA; Wion D; Mellstedt H; Focosi D; Karpel-Massler G; Heiland T; Halatsch M-E
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530

First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor

Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Review: JOURNAL OF DRUG TARGETING. 2016;24(5):373-385

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Meeting abstract: BLOOD. 2015;126(23):2912

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Review: CURRENT MEDICAL RESEARCH AND OPINION. 2015;31(12):2325-2330

Biosimilars - terms of use.

Declerck P; Mellstedt H; Danese S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458

The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.

Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31

The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770

Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway

Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184

Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region

Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Review: NATURE REVIEWS CLINICAL ONCOLOGY. 2014;11(9):509-524

Therapeutic vaccines for cancer: an overview of clinical trials.

Melero I; Gaudernack G; Gerritsen W; Huber C; Parmiani G; Scholl S; Thatcher N; Wagstaff J; Zielinski C; Faulkner I; Mellstedt H
Letter: LAKARTIDNINGEN. 2014;111(22-23):1011

[Cheaper with biosimilars, but safety comes first].

Mellstedt H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e13561

A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.

Mellstedt H; Daneshmanesh AH; Moshfegh A; Farsangl MH; Khan S; Mlkaelsson E; Vagberg J; Systrom S; Schultz J; Olin T; Ostorborg A
Meeting abstract: BLOOD. 2012;120(21):4583

Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia

Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Meeting abstract: BLOOD. 2012;120(21):1769

Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway

Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2012;72:3027

Dishevelled proteins are highly upregulated in chronic lymphocytic leukemia

Khan AS; Osterborg A; Moshfegh A; Mellstedt H
Other: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(4):587-591

First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.

Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Review: CANCER TREATMENT REVIEWS. 2012;38(1):68-75

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.

Patriarca C; Macchi RM; Marschner AK; Mellstedt H
Review: LAKARTIDNINGEN. 2011;108(42):2090-2094

[Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].

Mellstedt H; Gimsing P; Waage A
Review: LUNG CANCER. 2011;73(1):11-17

Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.

Mellstedt H; Vansteenkiste J; Thatcher N
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia.

Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Meeting abstract: CANCER RESEARCH. 2011;71:5011

Difference in expression of STAT3 and STAT5b in Swedish and Egyptian patients with activated b-cell subtype of diffuse large b-cell lymphoma

Jacobson T; Bahnassy AA; Lundahl J; Tamm KP; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Editorial comment: FUTURE ONCOLOGY. 2010;6(7):1065-1067

Implications of the development of biosimilars for cancer treatment.

Mellstedt H
Meeting abstract: CANCER RESEARCH. 2010;70:2171

Viral infection as an etiological risk factor for diffuse large B cell lymphoma (DLBCL): A comparative study between Egypt and Sweden

Jacobson TAS; Bahnassy AA; Moshfeg A; Zekri ARN; Porwit AP; Lundahl J; Mokhtar NM; Abdel-Hamid NA; Khaled HM; Mellstedt H
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):78

Biosimilars: issues facing clinicians

Mellstedt H
Review: LAKARTIDNINGEN. 2009;106(23):1563-1566

[Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].

Mellstedt H
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(11):1705-1710

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Osterborg A; Choudhury A
Published conference paper: ANNALS OF ONCOLOGY. 2008;19 Suppl 7:vii241-vii247

Overcoming immunosuppressive mechanisms.

Widén K; Mozaffari F; Choudhury A; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2008;19(3):411-419

The challenge of biosimilars.

Mellstedt H; Niederwieser D; Ludwig H
Editorial comment: ANNALS OF ONCOLOGY. 2007;18:1-2

Second European Breast Cancer meeting, 'Good risks and bad risks: Physicians' and patients' perspectives on adjuvant treatment for hormone-responsive early breat cancer', 20-21 May 2006, Stockholm, Sweden - Introduction

Mellstedt H
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):7-8

Biosimilars in oncology and hematology - what should a physician know

Mellstedt H; Ludwig H; Niederwieser D
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):8

G-CSF biosimilars - approval process, substitution and extrapolation

Niederwiesser D; Ludwig H; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2007;18(6):969-970

National integration of European standards.

Bajetta E; Gevorgyan A; Mellstedt H
Letter: LEUKEMIA. 2006;20(12):2204-2007

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.

Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Editorial comment: LANCET ONCOLOGY. 2006;7(9):700-701

Keynote comment: deliberations of a born-again cancer immunotherapist.

Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17 Suppl 10:x144-x154

The biology and treatment of chronic lymphocytic leukemia.

Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Editorial comment: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(21):3497

Introduction: ASCO-ESMO Consensus Statement on Quality Cancer Care

Horning SJ; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17(7):1061

Introduction: ASCO-ESMO consensus statement on quality cancer care.

Horning SJ; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17 Suppl 8:viii7-viii8

Cancer in developing countries: challenges and solutions.

Reeler AV; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2006;17 Suppl 8:viii24-viii31

Cancer initiatives in developing countries.

Mellstedt H
Review: SEMINARS IN ONCOLOGY. 2006;33(2 Suppl 5):S29-S35

Strategies in the management of alemtuzumab-related side effects.

Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2006;95:147-202

Clinical results of vaccine therapy for cancer: learning from history for improving the future.

Choudhury A; Mosolits S; Kokhaei P; Hansson L; Palma M; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2006;17:5

Welcome to TAT 2006!

Giaccone B; Lobbezoo M; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:24-31

Cancer initiatives in developing countries

Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2005;16(9):1411-1412

ESMO at 30: mission ongoing.

Kosmidis PA; Ludwig H; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2005;16(6):847-862

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.

Mosolits S; Ullenhag G; Mellstedt H
Review: EXPERT REVIEW OF VACCINES. 2005;4(3):329-350

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.

Mosolits S; Nilsson B; Mellstedt H
Published conference paper: ANNALS OF ONCOLOGY. 2005;16 Suppl 2:ii113-ii123

Biology and treatment of chronic lymphocytic leukemia.

Kokhaei P; Palma M; Mellstedt H; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):689A

T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.

Kiaii S; Mozaffari F; Lundin J; Rezvany R; Chudhury A; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):277A

Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.

Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):419A

Long-term Id vaccination combined with IL-12 or IL-12 and GM-CSF in early stage multiple myeloma patients

Hansson L; Abdalla AO; Rabbani H; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):288B

Comparison of antigen-loading strategies for DC-based immunotherapy of B-CLL.

Mellstedt H; Kokhaei P; Osterborg A; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):54A

Downregulating the fibromodulin gene by short interfering RNA causes B-CLL cell death.

Choudhury A; Derkow K; Mikaelsson E; Kokhaei P; Österborg A; Rabbani H; Mellstedt H
Letter: LEUKEMIA. 2003;17(11):2252-2254

T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage.

Rossmann ED; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Editorial comment: ANNALS OF ONCOLOGY. 2001;12(8):1037-1038

ESMO minimum clinical recommendations--the beginning of a process.
Published conference paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2000;910:254-261

Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma.

Mellstedt H; Fagerberg J; Frödin JE; Hjelm-Skog AL; Liljefors M; Markovic K; Mosolits S; Ragnhammar P
Editorial comment: ACTA ONCOLOGICA. 2000;39(7):763-764

Progress in the understanding of the biology and the treatment of multiple myeloma--a cure might be around the corner.

Mellstedt H
Published conference paper: ACTA ONCOLOGICA. 2000;39(7):797-800

Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.

Osterborg A; Henriksson L; Mellstedt H
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.

Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Review: SEMINARS IN IMMUNOPATHOLOGY. 1999;21(1):19-35

T cell receptor usage in malignant diseases.

Halapi E; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Review: LAKARTIDNINGEN. 1998;95(13):1405-1410

[Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].

Mellstedt H; Fagerberg J; Osterborg A
Addendum: INTERNATIONAL JOURNAL OF CANCER. 1996;65(5):714-715

Epstein Barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2 in vivo.

Laytragoon-Lewin N; Chen F; Avila-Carino J; Zou JZ; Mellstedt H; Ernberg I; Klein G
Other: CANCER RESEARCH. 1995;55(9):1824-1827

Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H
Review: CANCER JOURNAL. 1995;8(4):181-184

ANTIIDIOTYPES AND CANCER

FAGERBERG J; MELLSTEDT H
Show more

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI